Palvella Therapeutics, Inc. (PVLA) Cash from Financing Activities (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Cash from Financing Activities for 12 consecutive years, with $74.8 million as the latest value for Q4 2024.
- On a quarterly basis, Cash from Financing Activities rose 605.95% to $74.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $87.1 million, a 1641.78% increase, with the full-year FY2024 number at $87.1 million, up 1641.78% from a year prior.
- Cash from Financing Activities was $74.8 million for Q4 2024 at Palvella Therapeutics, up from $2.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $74.8 million in Q4 2024 to a low of -$14.8 million in Q4 2023.
- A 5-year average of $10.5 million and a median of $5.7 million in 2021 define the central range for Cash from Financing Activities.
- Biggest YoY gain for Cash from Financing Activities was 6939.5% in 2023; the steepest drop was 15993.55% in 2023.
- Palvella Therapeutics' Cash from Financing Activities stood at $75000.0 in 2020, then soared by 6434.67% to $4.9 million in 2021, then crashed by 98.1% to $93000.0 in 2022, then crashed by 15993.55% to -$14.8 million in 2023, then skyrocketed by 605.95% to $74.8 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Cash from Financing Activities are $74.8 million (Q4 2024), $2.4 million (Q3 2024), and $9.9 million (Q2 2024).